Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion.

Ann Surg Oncol. 2007 Feb;14(2):500-8. Epub 2006 Dec 6.
Baratti D, Kusamura S, Martinetti A, Seregni E, Oliva DG, Laterza B, Deraco M.
Department of Surgery, National Cancer Institute, Milan, Italy, marcello.deraco@istitutotumori.mi.it.

BACKGROUND: Recent phase I/II trials report encouraging results in selected patients with peritoneal mesothelioma (PM) treated with cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP). Circulating tumor markers have never been extensively investigated in the management of PM. We assessed the clinical role of markers in a large series of patients with pleural mesothelioma undergoing CRS and IPHP.

METHODS: Clinical data on 60 patients with PM operated with the intention to perform adequate CRS (residual tumor nodules <= 2.5mm) and IPHP were prospectively collected. Marker levels were determined pre-operatively, post-operatively, and routinely during long-term follow-up. Baseline diagnostic sensitivity, accuracy in monitoring response to mesothelioma treatment or tumor progression and prognosis significance were determined.

RESULTS: Baseline diagnostic sensitivity was 53.3% for CA125, 0 for CEA, 3.8% for CA19.9 and 48.5% for CA15.3. Forty-six patients underwent adequate cytoreduction and IPHP; gross residual tumor was left after the operation in fourteen. Postoperatively, CA125 became negative in 21/22 patients with elevated baseline levels undergoing adequate CRS and IPHP, while remained elevated in 9/9 patients with persistent macroscopic disease. CA125 became positive in 12/12 patients with elevated baseline levels developing mesothelioma disease progression after adequate CRS and IPHP. Baseline CA125 showed borderline prognostic significance only among patients not previously treated with systemic chemotherapy.

CONCLUSIONS: CA125 was elevated in the majority of patients with PM in the present series. Serial maker measurements paralleled tumor growth or regression after CRS and IPHP, suggesting the need of further studies to assess the role of CA125 in this clinical setting.

Source

PMID: 17151789 [PubMed - in process]
Click here to order or save article

If you have any questions regarding treatment options or your legal rights, please contact us.

Free Mesothelioma Information Packet

Enter your information to receive a comprehensive mesothelioma packet free of charge at your doorstep within 24 hours.

Yes   No

Mesothelioma Mesothelioma Treatment
Conventional Therapies Alternative Treatments Experimental Therapies Treatment by Stage Mesothelioma Doctors Mesothelioma Experts Clinical Trials Mesothelioma Clinics Ask Your Doctor Caregivers and the Aging Mesothelioma Research Review Studies Case Studies Etiological Studies Diagnostic Studies Therapy Studies Mesothelioma Resources Counseling Resources Mesothelioma Treatment Alerts
Asbestos Cancer Asbestos Exposure Mesothelioma News Veterans & Mesothelioma Mesothelioma Attorney FREE Case Evaluation Top Mesothelioma Doctors

Stephen Rush, M.D.
Dr. Stephen Rush currently serves as Clinical Associate Professor of Radiation Oncology at New York University Medical Center.

Michael Mulligan, M.D.
Dr. Michael S. Mulligan specializes in Thoracic Surgery and the diagnosis and treatment of lung cancer, mesothelioma and sarcoma at the University of Washington Medical Center.

David Rice, M.D.
Dr. David Rice is an Associate Professor and Assistant Surgeon at The University of Texas M.D. Anderson Cancer Center where he serves as the director of the Minimally Invasive Surgery and Mesothelioma programs.

This website is certified by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
verify here.